Skip to main content

Grafa News and Videos — Page 1162

Latest

Grafa

Johnson & Johnson’s Tecvayli delivers superior survival outcomes in blood cancer trial

Johnson & Johnson (NYSE:JNJ) reported positive late-stage clinical data for its blood cancer therapy Tecvayli (teclistamab-cqyv), demonstrating significant improvements in survival metrics for patients with relapsed or refractory multiple myeloma.

Read more: Johnson & Johnson’s Tecvayli delivers superior survival outcomes in blood cancer trial
Grafa

Bristol Myers drug halves risk of myeloma progression in pivotal trial

Bristol Myers Squibb (NYSE:BMY) announced positive late-breaking results from its Phase 3 SUCCESSOR-2 clinical trial, demonstrating that its experimental oral therapy mezigdomide significantly extends the time patients with relapsed or refractory multiple myeloma live without their disease worsening.

Read more: Bristol Myers drug halves risk of myeloma progression in pivotal trial

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift